Navigation Links
LX211 highlighted as potential disease modifying therapy for noninfectious uveitis
Date:10/29/2009

JERSEY CITY, NJ (October 26, 2009): An experimental drug, LX211 (LUVENIQ; oral voclosporin), may become the first approved oral treatment capable of modifying the course of uveitis, a group of serious eye conditions inevitably associated with either severe vision loss or substantial morbidity from steroid use. Results of international Phase 2/3 clinical trials conducted by Lux Biosciences, to be the subject of two podium presentations at the American Association of Ophthalmology (AAO) meeting and of a presentation at the satellite meeting of the American Uveitis Society (AUS) in San Francisco, October 24-27, highlight the ability of LX211 to control the inflammation that characterizes this potentially blinding eye disease and significantly reduce its rate of recurrence. Lux Biosciences plans to file an NDA and MAA for marketing approvals around year-end 2009 and early 2010 in the United States and Europe, respectively.

"The LX211-02 study was a double-masked, placebo-controlled, dose-ranging study that included 232 patients at 57 centers in North America, Europe and India with clinically inactive uveitis involving any location within the eye," said Bahram Bodaghi, M.D., Ph.D., Piti Salptrire Hospital Paris, France, who will present the study results on Monday October 26 at 8:50 am PT. "Results of this trial showed that LX211 was able to reduce recurrence of inflammation by 50% over placebo at the 0.4 mg/kg twice daily dose (p<0.05) and may therefore effectively increase the interval between inflammatory relapses to 24 months compared to 10 months with placebo."

"Given that inflammatory exacerbation is a direct trigger of vision loss," Prof. Bodaghi commented, "this result for LX211 is impressive. In addition to a marked reduction in recurrence of inflammation, visual acuity was preserved in this study. Moreover, these results suggest the potential for disease modification whereby treatment with LX211 alters the course of the disease leading u
'/>"/>

Contact: Joan Kureczka
JKureczka@comcast.net
415-821-2413
Kureczka/Martin Associates
Source:Eurekalert

Page: 1 2 3

Related biology technology :

1. Sugarcane as a Key Element Against Global Warming to be Highlighted at Green Week in Brussels
2. Bio-Matrix Scientific Group, Inc. Highlighted in LifeSciencesWorld.com Special Report; Stem Cell Market Projected to Exceed $8 Billion Worldwide by 2016
3. Inverseons Asthma Therapy Receives Notice of Allowance; Clinical Trial Highlighted in Lancet
4. Significant Anti-Tumor Activity and Extended Half-Life of NKTR-102 (PEG-irinotecan) Highlighted in Phase 1 Data Presented at EORTC-NCI-AACR Symposium
5. Pharmaxis Research Programs Highlighted at European Respiratory Society Congress
6. Pressure Cycling Technology (PCT) Highlighted in Five Podium Presentations at the Fifth International Conference on High Pressure; PBI Introduces the Patent-pending PCT Shredder at the Meeting
7. Epeius Biotechnologies Lead Product, Rexin-G for Metastatic Cancer, Aptly Highlighted by National Cancer Institute Journal
8. Depth of MedImmunes Respiratory Disease Research Program Highlighted at Annual Meeting of the American Thoracic Society
9. Nektars PEGylation Technology Enables Peptide Mimetic, Highlighted by Data Presented at 45th ERA-EDTA Congress
10. Stereotaxis Market Leadership Highlighted at Heart Rhythm 2008
11. Arius highlighted at AACR-NCI-EORTC 2007 International Cancer Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/22/2014)... Dec. 22, 2014  ( www.competitivehealth.com ) — Competitive ... medical bill review and advocacy service, has signed an ... WellCard Savings discount health services marketplace. 63% ... more than they expected to pay. As part of ... costs, WellCard Savings is pleased to offer medical bill ...
(Date:12/22/2014)... 22, 2014 Fertility Associates of Memphis ... Bank USA , a network of more than 20 ... partnership, patients have fast access to a national pool ... IVF . Fertility Associates of Memphis is the only ... treatment option. , Dr. William Kutteh , director ...
(Date:12/19/2014)... BioPlus Specialty Pharmacy (BioPlus), one ... of Nick Maroulis, Pharm.D. to the newly created position ... In this position, Dr. Maroulis will continue to manage ... of our multi-site pharmacies as the company expands. Dr. ... that time he has served in many different capacities ...
(Date:12/19/2014)... Dec. 19, 2014 Bina Technologies, Inc. (Bina, ... that they have been acquired by Roche (SIX: RO, ... privately held company that provides a big data platform ... (NGS) data for the academic and translational research markets. ... and will continue to focus on development of their ...
Breaking Biology Technology:WellCard Savings Announces CoPatient Medical Bill Review Service for Members 2Fertility Associates of Memphis Announces Partnership with Donor Egg Bank USA 2Fertility Associates of Memphis Announces Partnership with Donor Egg Bank USA 3BioPlus Specialty Pharmacy Promotes Dr. Nick Maroulis to Vice President of Specialty Pharmacy Services 2Bina Technologies is acquired by Roche. 2Bina Technologies is acquired by Roche. 3
... 4, 2011 Radient Pharmaceuticals Corporation (OTCQX:RXPC) (OTCPK:RXPC), a ... (IVD) cancer tests, today announced that all six proxy ... The Company,s proxy statement was filed with ... is available at www.sec.gov and on the ...
... N.C., Nov. 4, 2011 NeuroCog Trials, Inc. today ... the position of Chief Operating Officer.  In this newly ... continued growth and expansion of NeuroCog Trials, business, research ... research and development for pro-cognitive therapies across a wide ...
... 4, 2011 Major milestone achieved in ... of patients with refractory ascites due to liver cirrhosis. ... and Vienna General Hospital (AKH Wien) reported that the ... were performed at Vienna General Hospital in October, under ...
Cached Biology Technology:Radient Pharmaceuticals Announces Proxy Resolutions Approved at Special Meeting of Stockholders 2NeuroCog Trials Appoints Industry Executive Michael Hufford, Ph.D. to Chief Operating Officer 2The Medical University of Vienna and Vienna General Hospital Perform the First two Commercial Implants Worldwide of Sequana Medical's ALFApumpĀ® System 2
(Date:12/3/2014)... , Dec. 2, 2014   Marvin Test ... innovative test solutions for military, aerospace, and manufacturing ... of its successful TS-900 PXI semiconductor test ... features of high-end systems to customers at a ... compared to traditional ATE. "Our ...
(Date:11/21/2014)... -- Earlier this year Donald Spector , Chairman of ... the most prolific inventors in the world, got a ... to third party agencies. Spector envisioned this technology even ... earliest known patents in this area. Now major technology ... care, elder care and hospital applications. This technology has ...
(Date:11/21/2014)... JOSE, Calif. , Nov. 20, 2014   ... global leader in microcontroller (MCU) and touch technology solutions, ... digital temperature sensors with the widest V cc ... delivers higher temperature accuracy and faster I 2 C ... registers and serial EEPROM memory making them ideal for ...
Breaking Biology News(10 mins):Marvin Test Solutions Brings New Capabilities to PXI-Based Semiconductor Test with TS-960 2Marvin Test Solutions Brings New Capabilities to PXI-Based Semiconductor Test with TS-960 3Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 2Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 3Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 4Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 2Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 3Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 4
... Engineering established to be a world leading centre in ... Excellence (RCE) supported by NRF and MOE, bringing the ... 2007 , , 1. The National Research Foundation (NRF) and ... support for a Research Centre of Excellence (RCE) called ...
... of reports, the ACSS has collected a number of stories ... that will improve everyone,s wellbeing. The impact of social science ... re-employment to healthy diets and the wellbeing of children. ... will present her research on the value of fathers and ...
... 10, 2010) The American Psychiatric Association today released ... of Diagnostic and Statistical Manual of Mental Disorders (DSM). ... consideration for DSM, which is the standard classification of ... professionals, and is used for diagnostic and research purposes. ...
Cached Biology News:NTU sets up centre on micro-organism research for environmental engineering and sustainability 2NTU sets up centre on micro-organism research for environmental engineering and sustainability 3NTU sets up centre on micro-organism research for environmental engineering and sustainability 4APA announces draft diagnostic criteria for DSM-5 2APA announces draft diagnostic criteria for DSM-5 3APA announces draft diagnostic criteria for DSM-5 4APA announces draft diagnostic criteria for DSM-5 5
... The lyophilization stabilizer is designed ... process and for long-term storage. ... toxic ingredients. It is a ... pH 7.2, and is superior to ...
... coating stabilizer is designed for stabilizing ... and antibodies for immunoassay development. ... during the coating and drying process ... It can also works as a ...
... Clinical is Tecans open platform for clinical ... safety and performance in the clinical diagnostic ... by flexible barcode reading and sample traceability ... the system complies with the IVD-Directive* established ...
... the smallest thermal cyclers on the market, which ... 0.5ml (20 samples) or 0.2ml microtube (25 samples) ... and cooling rate of 3.6C/sec and 2.0C/sec respectively ... Fast track programming with new quick dial facility ...
Biology Products: